Personalis, Inc. (NASDAQ:PSNL) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP cut its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 70.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 124,082 shares of the company's stock after selling 302,794 shares during the quarter. GSA Capital Partners LLP owned 0.23% of Personalis worth $668,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. ARK Investment Management LLC raised its position in Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company's stock worth $38,120,000 after buying an additional 723,637 shares during the last quarter. Acadian Asset Management LLC increased its stake in Personalis by 6.7% in the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company's stock worth $1,237,000 after purchasing an additional 66,128 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Personalis by 144.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company's stock valued at $1,224,000 after buying an additional 485,822 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Personalis by 58.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company's stock valued at $142,000 after buying an additional 34,900 shares during the period. Finally, Semanteon Capital Management LP purchased a new position in shares of Personalis during the third quarter valued at $375,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $7.25 price target on shares of Personalis in a report on Thursday, November 7th. BTIG Research lifted their target price on Personalis from $5.50 to $7.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Finally, HC Wainwright lifted their target price on Personalis from $7.50 to $9.00 and gave the company a "buy" rating in a research report on Monday, August 19th.

Personalis Stock Up 2.8 %

Personalis stock traded up $0.10 during trading hours on Tuesday, hitting $3.69. The stock had a trading volume of 698,550 shares, compared to its average volume of 727,355. Personalis, Inc. has a 1-year low of $1.12 and a 1-year high of $7.20. The stock's fifty day moving average is $5.03 and its two-hundred day moving average is $3.49.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The firm had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same period last year, the company posted ($0.51) EPS. Analysts predict that Personalis, Inc. will post -1.33 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.